Valproatereatment of Acute Mania: A Placebo-Controlled

Archives of General Psychiatry

Volumn 48, Issue 1, 1991, Pages 62-68

  Pope, Harrison G ^a,b   Mcelroy, Susan L ^a,b   Keck, E ^a,b   Hudson, James I ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM CARBONATE; LORAZEPAM; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; MANIA; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; LORAZEPAM; MALE; MIDDLE AGE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VALPROIC ACID;

EID: 0026088931     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1991.01810250064008     Document Type: Article

References (55)

1. Dunner DL. Mania. In: Tupin JP, RI, Harnett Harnettook of Clinical P2ndha Northvale, A Inc; 1988:97-109.
2. Sachs GS. Adjuncts and alternatives to lithium therapy for bipolar affective disortivClinchiatry. 1989;50:12(suppl):31-39.
3. Harrow M, Goldberg JF, Grossman LS, Meltzertcome in manic disorders: a naturalistic follow-uprch Gen Psychiatry. 1990;47:665-671.
4. Weissman MM, Leaf PJ, Tischlerzer DG, Karnoruce ML, Florioffective disorders in five United States communities. Psychol Med. 1988;18:141-153.
5. Rimm Richensupdate on sodium vPharmacothera 1985;5:171-184.
6. Lambert P-A. te and prophylactic therapies of patients with affective disorders using v(diprEmricOkuma MülleAnticonvulsantsisorders. Amsterdam, the Netherlands: EM1984:33-44.
7. SemadEtude clinique de l'seffect normothymique du dipropylacetamide. Acta Psychiatr Belg. 1976;76:458-466.
8. Emrich HM, Dose M, von Zerssen D. Sodium valproate, carbanazepine, and oxcarbazepine in patients with affective disorders. J Affective Disord. 1985;8:243-250.
9. Brennan MJW, Sandyk R, Borsook D. Use of sodium valproate management of affective disorders: basic and clinical aspects. In: Emrich Okumauller AA, eds. Anticonvulsants in Disorders. Amsterdam, the Netherlands: Excerpta Medica; 1984:55-65.
10. Puzynski S, Valproic aide amide in the treatment of affective and schizoaffective disorders. J Affective Disord. 1984;6:115-121.
11. VencvskyE, Soucek k, Zatecka I. Comparison of side effects of lithium and dipropylacetamide (Depamide).Cesk Psychiatr. 1983;79:223-227.
12. Post RM, Berrettini W, Uhde TW, Kellner C. Selective reesponse to the anticonvulsant carbamazepine in mamic-depressive illness: a case study. J Clin Psychopharmacol. 1984;4:178-185.
13. PrasadAJ. The role of sodium valproate as an anti-manic agent. Pharmatherapeutica. 1984;4:6-8.
14. Lovett L, Watkins SE, Shaw DM. The use of alternative drug therapy in nine patients with recurrent affective disorder resistant to conventional prophylaxis. Biol Psychiatry. 1986;21:1344-1347.
15. McElroy SL, Pope HG Jr, Keck PE Jr, Hudson JI. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatr Psychobiol. 1988;3:81-85.
16. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in psychiatric disorders: literature review and clinical guidelines. J clin Psychiatry. 1989;50(suppl):23-29.
17. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities, II: US experience since 1984. Neurology. 1989;39 (2 pt 1):201-207.
18. DreifValproicpatic fatalities: revised table. Neurology. 1989;39:1558.
19. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnosticstical Manual of Mental Disorders, Third Revised Edition. Washington, DC: American Psychiatric Association; 1987.
20. Spitzerlliams JBW, Gibbon M. Structured Clinical Interview for DSM-III-RNew York, NY: New York State Psychiatric Institute; 1989.
21. Young RC, Biggs JT,Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429-435.
22. Spitzer RL, Gibbon M, Endicott J. Global Assessment Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health; 1976. US Dept of Health, Education, and Welfare publication (ADM) 76-338.
23. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
24. Hudson JI, Lipinski JF,Frankenburg FR,Grochocinski VJ, Kupfer DJ.Electroencephalographic sleep in mania. Arch Gen Psychiatry. 1988;45:267-273.
25. Busch FN, Miller FT, Weiden PJ.A comparison of two adjunctive treatment strategies in acute mania. J Clin Psychiatry. 1989;50:453-455.
26. Schoum, Juel-Nielson N, Strömgren E, Voldby H. Treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17:250-260.
27. Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry. 1963;109:56-65.
28. Goodwin FK, Murphy DL, Bunney WE Jr. Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study Arch Gen Psychiatry. 1969;21:486-496.
29. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry. 1967;16:118-126.
30. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT.Corrolates of antimanic response to carbamazepine.Psychiatry Res. 1987;21:71-83.
31. Muller AA,Stoll KD.Carbaoxcarbaztreatmentmanic syndromes: studies in Germany. In: EmricOkuma Muller AA, eds. Anticonvulsantsisorders. Princeton, NJ: ExcM1984:139-147.
32. Chambers CA, Naylor controlled trial of L-tryptophan BrJychiatry. 1978;132:555-559.
33. Chouinardg SN, Annableontrolled clinical trial of L-tryptophannia. Biol Psychiatry. 1985;20:546-557.
34. Giannini AJ, Houser WL Jr, Loisellennini MC, Price WA. Antimanicof verapamil.hiatry. 1984;141:1602-1603.
35. Dubovskynks RD, Allen S, Murphy J. Calcium antagonists in mania: a double-bliverapamil.y Res. 1986;18:309-320.
36. Dose M, EmricCordvZerssen of calcium antagonists in mania. P 1986;11:241-243.
37. RackFritSchwStuttvZerssen WdBPaManienPsycN 1976;222:223-243.
38. EmricvZersMöKisslinging C, Scietsch HJ. Action of propranololcomparison of effects of the d-nd the sP 1979;12:295-304.
39. JanicSharmEastComatyavis JM. A doubleblind placebo-coclonidinereatment of acute mania. Psychop 1989;25:243-245.
40. KriegBerger M. Treatment of mania with the cholinomimetic RS86. Psychiatry. 1986;148:613.
41. Van BerkestidMeulenFlenDolsvan den HoofRS86manic disorder. Biol Psychiatry. 1990;27:109-112.
42. AldenSchlegeler I, WetzAntimanicof the cD60dplacebo-CNeuro- p1986;9(suppl4):553-555.
43. Lloyd KG, MorsePsycGABAergicn: Meltzer. PTheharmacology:on of Progress. New York, NY: Raven Press; 1987:183-195.
44. BartholiniKG, Morselli PMorselli Mood Disorders: Experimentall Research. New York, NY: Raven Press; 1986.
45. Emrichon ZersKissMöWindorfer Effect of sodium valproate: the GABA-hypothesidisorders. PN 1980;229:1-16.
46. BerrettiniRM. GABA in affective illness. In: Post RM, Ballenger Neurobiology of Mood Disorders. Baltimore, Md: Williams &Wilkins; 1984:673-685.
47. Potter WZ, RudorManjiPotential new pharmacotherapies for refractory depression. In: TasmGoldfingeran CA, eds. American Psychiatric Press Review of Psychiatry. Washington, DC: American Psychiatric Press; 1990;9:145-169.
48. Gernerairbanks L, Anderson GM, Young JG, ScheLinnoilaare TA, Shaywitzen DJ. CSF neurochemistry manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry. 1984;141:1533-1540.
49. ChouClonazepameatment of psychiatric disorders. In: McElroype HG Jr, eds. Use of Anticonvulsants Recent Advances. Clifton, NJ: Oxford Health Care I1987:43-58.
50. Wolf ME, AlmyToll M, Mosnaimnia associated with the use of baclofen.chiatry. 1982;17:757-759.
51. Arnold ES, Rudd S, Kirshnerc psychosis following rapid withdrawalbaclofen.chiatry. 1980;137:1466-1467.
52. Post RM, Stoddard FJ, GilliBuchsRunklelack KE, Bunney. Alterations in motor activity, sleep, and biochemistry in a cycling manic-depressiveen Psychiatry. 1977;34:470-477.
53. Post RM, RubinUhde Roy-BLinnRosoffa A, CowdDysphoriclinical and biological correlates. Arch Gen Psychiatry. 1989;46:353-358.
54. Perez dea Mora M, PossaTapiTeraPalaFoxe HokfLjungdahlstration of central gamma-aminobutyratecontaining nerve terminals by means of antibodies against glutamate decarbox- yN 1981;6:875-895.
55. Borsookect D. Effect of anticonvulsants on circadin rhythms: implications for major affective disorder and primary sleep disorders. In: McElroype HG, Jr, eds. Use of Anticonvulsants Recent Advances. Clifton, NJ: Oxford Health Care I1988:95-114.